Attached files

file filename
8-K/A - 8-K/A - Healthcare Corp of Americav345380_8ka.htm
EX-99.2 - EXHIBIT 99.2 - Healthcare Corp of Americav345380_ex99-2.htm
EX-99.1 - EXHIBIT 99.1 - Healthcare Corp of Americav345380_ex99-1.htm

 

 

         HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES 
         Index to Financial Statements 
 
         
         
Consolidated Balance Sheet:        
     December 31, 2012 and March 31, 2013        F-1 
         
Consolidated Statements of Operations:        
     Three months ended March 31, 2012 and 2013        F-2 
         
Consolidated Statements of Cash Flows:         
     Three months ended March 31, 2012 and 2013        F-3 
         
Notes to Financial Statements:        
     March 31, 2013        F-4 

 

 

 
 

 

 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES
   Consolidated Balance Sheet
 
       
    Audited / Restated    Unaudited 
    December 31,    March 31, 
    2012    2013 
           
ASSETS          
  Current assets:          
    Cash  $1,791,089   $408,978 
    Accounts receivable   572,637    2,068,835 
    Rebates receivable   1,323,474    1,544,906 
    Other receivable   40,867    299,946 
    Inventory   573,540    457,004 
    Prepaid Loan Fees   488,229    315,913 
      Total current assets   4,789,836    5,095,582 
           
  Property and equipment, net of accumulated depreciation, restated   1,114,055    1,409,773 
           
  Other assets:          
     Security deposits   66,131    66,131 
     Other   58,743    1,000 
    124,874    67,131 
           
           
Other Assets          
           
           
 Total Other Assets        —   
      Total assets  $6,028,765   $6,572,486 
           
           
LIABILITIES          
  Current liabilities:          
    Accrued Compensation       $—   
    Accounts payable  $4,520,233   $5,445,746 
    Accrued expenses   453,057    537,134 
    Accrued taxes payable   11,071    32,870 
    Customer deposits        804,698 
    Note payable   4,947,613    4,947,613 
    Reedemable preferred stock   458,800    458,800 
    Warrant liability   518,587    518,587 
    Current portion of long term debt   137,703    169,745 
      Total current liabilities   11,047,064    12,915,193 
  Long-term  liabilities:          
     Convertible Notes Payable        —   
      Total long-term liabilities        —   
           
      Total current liabilities   11,047,064    12,915,193 
           
  Long term liabilities:          
   Deferred rent   64,133    59,909 
   Leases payable   399,382    494,659 
           
     Total long term liabilities   463,515    554,568 
           
  Total Liabilities   11,510,579    13,469,761 
           
STOCKHOLDERS' DEFICIT          
  Common stock, no par value, 50,000,000 authorized,          
   37,879,809 and 40,000,009 shares issued and outstanding   3,556,056    3,936,056 
  Stock redemption   (100,000)     
  Accumulated deficit, restated   (8,937,860)   (10,833,331)
      Total stockholders' equity   (5,481,804)   (6,897,275)
      Total liabilities and stockholders equity  $6,028,775   $6,572,486 

 

 The accompanying notes are an integral part of these statements.

 

 

F-1
 

 

               HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES 
               Consolidated Statement of Operations 
               Unaudited 
               

 

   Three months  Three months
   Ended  Ended
   March 31,  March 31,
   2012  2013
       
Sales  $5,677,089   $11,961,723 
           
Cost of Sales   4,767,120    10,605,500 
           
Gross Profit   909,969    1,356,223 
           
General and administrative expenses:          
  Wages and taxes   549,242    862,532 
  Stock based compensation        480,000 
  Commissions   243,512    443,848 
  Advertising and marketing   10,556    24,449 
  Legal and professional   125,384    416,471 
  Computer and internet   1,152    20,733 
  Travel and entertainment   26,476    102,956 
  Insurance   157,657    261,573 
  Office and postage   33,388    62,137 
  Rent   57,905    50,919 
  Depreciation and amortization   51,428    74,693 
  Bad debts          
  Other office and miscellaneous   25,454    43,577 
    Total operating expenses   1,282,154    2,843,888 
    Income/(Loss) from operations   (372,185)   (1,487,665)
           
Other income (expense):          
  Interest income        84 
  Interest (expense)   (6,179)   (407,891)
  Other (expense)   (2,915)     
   Income/(Loss) before taxes   (381,279)   (1,895,472)
           
Provision/(credit) for taxes on income   —      —   
    Net Income/(loss)  $(381,279)  $(1,895,472)
           
           
Basic earnings/(loss) per common share  $(0.01)  $(0.05)
           
Weighted average number of shares outstanding   38,939,909    40,250,009 

 

 The accompanying notes are an integral part of these statements.

 

F-2
 

 

 HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES 
 Consolidated Statement of Cash Flows 
 Unaudited 
 

 

   March 31,  March 31,
   2012  2013
           
 Cash flows from operating activities:          
  Net income (loss)  $(381,279)  $(1,895,472)
           
 Adjustments to reconcile net (loss) to cash          
   provided (used) by operating activities:          
     Common stock issued for services        480,000 
     Depreciation and amortization   51,428    74,693 
      Amortization of capital raising expenses        172,316 
   Change in current assets and liabilities:          
     Accounts receivable   275,115    (1,496,198)
     Rebates        (221,432)
     Other receivables        (259,079)
     Inventory   (24,879)   116,536 
     Prepaid expenses and other current assets   (127,000)   57,743 
     Other assets          
     Accounts payable and accrued expenses   (2,327,035)   1,031,400 
      Deferred rent   —      (1,415)
       Customer deposits   564,824    804,698 
         Net cash flows from operating activities   (1,968,826)   (1,136,210)
           
 Cash flows from investing activities:          
       Purchase of fixed assets, restated   (31,292)   (370,411)
           
         Net cash flows from investing activities   (31,292)   (370,411)
           
 Cash flows from financing activities:          
       Proceeds from sale of common stock   —        
       Proceeds from notes payable          
       Redeemable preferred stock          
       Warrants issued          
       Redemption of common stock   —        
        Proceeds/(payments) from capital leases   (64,601)   124,510 
           
         Net cash flows from financing activities   (64,601)   124,510 
 Net cash flows   (2,064,719)   (1,382,111)
           
 Cash and equivalents, beginning of period   3,354,385    1,791,089 
 Cash and equivalents, end of period  $1,289,666   $408,978 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS FOR:          
     Interest  $(43,038)  $(132,339)
     Income taxes       $—   

 

 The accompanying notes are an integral part of these statements.

 

F-3
 

 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013 

 

Note 1 - Summary of Significant Accounting Policies

 

     General Organization and Business

 

Healthcare Corporation of America (“HCCA”) and its subsidiaries, are New Jersey Corporations. The consolidated companies are primarily engaged in the health benefits industry which provides benefit management services and mail order pharmacy fulfillment. The subsidiaries are Prescription Corporation of America Benefits (“PCB”) and Prescription Corporation of America (“PCA”). HCCA was incorporated on February 26, 2008, PCB was incorporated on October 7, 2010, and PCA was incorporated on January 11, 2008.

 

Basis of presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Changes in classification of 2012 amounts have been made to conform to current presentations.

 

Basis of consolidated

 

The consolidated financial statements include the accounts of HCCA and its wholly-owned subsidiaries PCA and PCB, (collectively, the “Company”). All significant intercompany transactions and balances have been eliminated in consolidation.

 

Use of estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Cash and cash equivalents

 

For purposes of the statement of cash flows, we consider all cash in banks, money market funds, and certificates of deposit with a maturity of less than three months to be cash equivalents. For cash management purposes, the Company concentrates its cash holdings in multiple checking accounts at Chase Bank. The balances in these accounts may exceed the federally insured limit of $250,000 by the Federal Deposit Insurance Corporation in case of bank failure.

 

Property and Equipment

 

The Company values its investment in property and equipment at cost less accumulated depreciation. Depreciation is computed primarily by the straight line method over the estimated useful lives of the assets ranging from five to thirty-nine years.

 

Inventory

 

Inventory is recorded at lower of cost or market; cost is computed on a first-in first-out basis. The inventory consists of finished goods. Inventory at year end was $573,540.

 

F-4
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

Accounts receivable

 

Trade receivables are carried at original invoice amount. Accounts receivable are written off to bad debt expense using the direct write-off method. Management determines uncollectible accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions and by using historical experience applied to an aging of accounts. Recoveries of trade receivables previously written off are recorded when received.

 

Revenue recognition:

 

Benefit management services revenues are recognized over the period in which members are entitled to receive benefits. Mail order pharmacy fulfillment sales consist of amounts due from 3rd party payors and member copayments.

 

Rebates received from the pharmaceutical manufacturers are recorded as reduction of cost of revenues and the portion of the rebate payable to customers is treated as reduction of revenue.

 

Stock-based compensation

 

The Company accounts for equity awards based on the fair value of the common stock at the date of issue. Expense is recognized upon vesting.

 

Fair value of financial instruments and derivative financial instruments

 

We have adopted Accounting Standards Codification regarding Disclosure About Derivative Financial Instruments and Fair Value of Financial Instruments. The carrying amounts of cash, accounts payable, accrued expenses, and other current liabilities approximate fair value because of the short maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment, and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. We do not hold or issue financial instruments for trading purposes, nor do we utilize derivative instruments in the management of foreign exchange, commodity price or interest rate market risks.

 

Federal income taxes

 

Deferred income taxes are reported for timing differences between items of income or expense reported in the financial statements and those reported for income tax purposes in accordance with Accounting Standards Codification regarding Accounting for Income Taxes, which requires the use of the asset/liability method of accounting for income taxes. Deferred income taxes and tax benefits are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and for tax loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred taxes are provided for the estimated future tax effects attributable to temporary differences and carryforwards when realization is more likely than not.

 

Net Income Per Share of Common Stock

 

We have adopted Accounting Standards Codification regarding Earnings per Share, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. We do not compute fully diluted earnings per share because they are antidilutive.

 

F-5
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

    Internal Website Development Costs

 

Under ASC350-50, Website Development Costs, costs and expenses incurred during the planning and operating stages of the Company's website are expensed as incurred.  Under ASC 350-50, costs incurred in the website application and infrastructure development stages are capitalized by the Company and amortized to expense over the website's estimated useful life or period of benefit.  

 

    Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of long-lived assets and the related estimated remaining lives at each balance sheet date.  The Company records an impairment or change in useful life whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or the useful life has changed.

 

    Deferred Offering Costs

 

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed.  At the time of the completion of the offering, the costs are charged against the capital raised.  Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. During 2012, the Company incurred $689,264 in offering costs which were capitalized and amortized over the life of the loan.

 

    Common Stock Registration Expenses

 

The Company considers incremental costs and expenses related to the registration of equity securities with the SEC, whether by contractual arrangement as of a certain date or by demand, to be unrelated to original issuance transactions.  As such, subsequent registration costs and expenses are reflected in the accompanying financial statements as general and administrative expenses, and are expensed as incurred.

 

Risk Concentration

 

The Company grants unsecured credit to its customers. The Company continuously monitors the payment performance of its customers to ensure collections and minimize losses. Management does not believe that significant credit risks exist at December 31, 2012. Management has determined that an allowance for doubtful accounts is not necessary at December 31, 2012 since no losses have been incurred to date.

 

Advertising:

 

The Company expenses all costs of advertising as incurred. The advertising costs included in general and administrative expenses for the year ended December 31, 2012 was $78,446 and $4,894 at March 31, 2013.

 

 

Note 2 – Restatement

 

The financial statements have been revised to correct an error in accounting for the Company’s sales, accounts receivable, cost of sales, accounts payable, capital leases, accrued rent and accrued taxes. In accordance with U.S. GAAP, the Company calculated and recognized adjustments accordingly.

 

 

F-6
 

 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

The following table represents the effects of the restated statements as of December 31, 2011 and 2012.

 

  

Restated

12/31/2011

  

Original

12/31/2011

  

Restated

12/31/2012

  

Original

12/31/2012

 
Accounts receivable  $—          $572,637   $1,220,065 
Rebates Receivable  $—     $—     $1,323,474   $1,638,000 
Property and Equipment, net  $824,284   $338,631   $—     $—   
Accounts payable  $6,301,691   $2,559,592   $4,520,223   $1,514,857 
Lease payable  $510,647   $—     $—     $—   
Deferred rent  $56,402   $—     $—     $—   
Accrued taxes  $6,391   $—     $—     $—   
Sales  $24,928,065   $28,226,088   $28,663,284   $38,401,140 
Cost of Sales  $23,919,518   $25,406,749   $24,068,906   $31,650,232 
General and Administrative expenses  $4,881,266   $2,876,835   $—     $—   
Accumulated deficit  $(5,592,349)  $(1,762,462)  $(8,937,860)  $(4,970,540)

 

Note 3 – Commitments and Contingencies

 

Operating leases

 

The Company leases office space in Denville, New Jersey and office equipment. The office lease requires the following minimum rental payments:

 

Minimum Rental Payments 
    Premise 
2014   $196,189 
2015    177,578 
2016    154,347 
2017    130,613 
2018    101,569 
Thereafter    —   
    $760,297 

 

 

F-7
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

Rent expense for the period ended December 31, 2012 was $182,455 and $42,575 for the period ended March 31, 2013.

 

The Company also has a deferred rental agreement with their landlord. The Company has recorded deferred rent at December 31, 2012 of $72,888 and $65,814 on March 31, 2013. The deferral amortizes over the life of the lease that expires in February 2017.

 

Note 4 – Employment Agreements

 

In 2012, the Company entered into employment agreements with four of its senior officers. The agreements specify an aggregate guaranteed salaries of $930,000 each year of employment. The agreements allow the Company to terminate these individuals for cause. At December 31, 2012 the Company has four remaining agreements.

 

Note 5 – Litigation

 

During 2012, the Company filed suit against its past adjudicator of claims for overcharges, over payment on claims, errors and misclassifications, and rebates owed from drug manufacturers for over $5 million. The Company’s General Counsel has advised management that the outcome of this lawsuit is undeterminable, and as a result, the Company has not recorded any receivable and will record any revenue when and if received. The adjudicator of claims filed a counterclaim in the amount of $2.9 million for amounts it claims are owed to it by the Company

 

On August 14, 2012, the Company entered into a settlement with a shareholder to buy back 500,000 shares of common stock for $100,000. The settlement also called for the Company to pay $50,000 to the shareholder to settle claims against the company. As of December 31, 2012, the Company had not received the 500,000 shares of common stock but had paid the settlement. The Company received these shares in February 2013. A stock redemption was recorded on December 31, 2012 in the amount of $100,000.

 

Note 6 - Common Stock

 

During 2011, the Company issued 10,469,109 shares of common stock with a fair value range of $0.03 to $0.31 to its full-time employees and consultants in recognition of their efforts to assist and develop the Company. Stock-based compensation costs amounted to $410,529. These shares vested immediately and are freely tradable.

 

During 2012, the Company issued 2,120,200 shares of common stock with a fair value range of $0.01 to $0.31. These shares are freely tradable.

 

During 2012, the Company settled a suit with a shareholder to repurchase 500,000 shares of its common stock. These shares were recorded as a stock redemption for $100,000 and the shares were received in February 2013.

 

During the first quarter of 2013, The Company issued 500,000 fully vested shares to key employees and consultants. The Company has recognized a one-time stock based compensation in the amount of $480,000.

 

F-8
 

 

 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

Note 7 – Property and Equipment

 

The Company values its investment in property and equipment at cost less accumulated depreciation.

 

Following is a detailed break-out of the Company’s property and equipment:

 

   12/31/2012   3/31/2013 
Furniture and fixtures  $1,374,126   $1,744,539 
Leasehold improvements   10,162    10,162 
    1,384,288    1,754,701 
Accumulated depreciation   (270,233)   (344,928)
Net property and equipment  $1,114,055   $1,409,773 

 

The Company recorded depreciation expense of $205,997 and $74,693 for the year ended December 31, 2012 and period ended March 31, 2013, respectively.

 

F-9
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

Note 8 – Long Term Debt – Leases

 

Long-term debt at March 31, 2013 is summarized as follows:

 

   Due within One Year   Due after One Year   Total 3/31/2013 

Note payable in monthly installments

of $2,140 including 8% interest, secured

by equipment

  $22,867   $117,703   $140,570 

Note payable in monthly installments

of $1,712 including 8% interest, secured

by equipment

   18,294    132,658    150,952 

Note payable in monthly installments

of $1,117 including 12% interest, secured

by equipment

   9,224    29,638    38,862 

Note payable in monthly installments

of $1,764 including 12% interest, secured

by equipment

   18,488    11,861    30,349 

Note payable in monthly installments

of $1,672 including 12% interest, secured

by equipment

   17,529    11,246    28,775 

Note payable in monthly installments

of $764 including 7% interest, secured

by equipment

   7,894    13,690    21,584 

Note payable in monthly installments

of $1,383 including 6.2% interest, secured

by equipment

   15,324    12,133    27,457 

Note payable in monthly installments

of $212 including 7% interest, secured

by equipment

   2,208    3,615    5,823 

Note payable in monthly installments

of $1,159 including 6.9% interest, secured

by equipment

   12,076    19,755    31,831 

Note payable in monthly installments

of $763 including 6.9% interest, secured

by equipment

   7,954    13,006    20,960 

Note payable in monthly installments

of $3,663 including 12.3% interest, secured

by equipment

   26,324    129,354    155,678 
   $158,182   $494,659   $652,841 

 

Future maturities of long term debt are as follows:

 

     
March 31, 2015   $153,573 
March 31, 2016    127,907 
March 31, 2017    115,671 
March 31, 2018    97,508 
    $494,659 

 

 

 

F-10
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

Note 9 - Income Taxes

 

The provision (benefit) for income taxes for the years ended December 31, 2011 and 2012 were as follows:

 

   Year Ended December 31,
   2011  2012
       
Current Tax Provision:          
Federal-          
         Taxable income  $—     $—   
             Total current tax provision  $—     $—   
           
Deferred Tax Provision:          
Federal-          
             Loss carryforwards  $1,319,537   $1,137,473 
               Change in valuation allowance   (1,319,537)   (1,137,473)
              Total deferred tax provision  $—     $—   
           


The Company had deferred income tax assets as of December 31, 2011 and 2012, as follows:

 

   December 31,
   2011  2012
       
  Loss carryforwards  $1,901,399   $3,038,872 
  Less - Valuation allowance   (1,901,399)   (3,038,872)
     Total net deferred tax assets  $—     $—   

 

The Company provided a valuation allowance equal to the deferred income tax assets for the years ended December 31, 2011 and 2012, because it is not presently known whether future taxable income will be sufficient to utilize the loss carryforwards.

 

F-11
 

 

HEALTHCARE CORPORATION OF AMERICA AND SUBSIDIARIES

 NOTES TO FINANCIAL STATEMENTS

March 31, 2013

 

As of December 31, 2011, and 2012, the Company had approximately $5,592,349 and $8,937,859, respectively, in tax loss carryforwards that can be utilized in future periods to reduce taxable income, and will begin to expire in the year 2035.

 

Note 10 – Note Payable and Preferred Stock

 

On September 19, 2012, the Company entered into a bridge loan agreement that created debt of $5,925,000, which is shown on the Balance Sheet as Note Payable of $5,466,200, Warrant Liability of $518,587 and Redeemable Preferred Stock of $458,800. Additionally, warrants were attached to the note payable allowing the holders to purchase 296,250 shares of common stock of Selway Capital Acquisition Corporation (“Selway”). The warrants have a strike price of $15 per share and have a life of 4 years. The Company has valued these warrants at $1.7505 using the Black Scholes pricing method.

 

In the event that the merger does not take place the preferred stock is valued at zero or convertible to 3.7% of the outstanding common shares of HCA stock. As of December 31, 2012, there were 40,000,009 outstanding shares, 3.7% of which would be 1,480,000 shares. The last recorded transaction for sales of HCA common stock was in June 2012 at $0.31 per share. Due to a lack of marketability and liquidity, The Company has determined this to be a conservative value for the Redeemable Preferred Stock.

 

The Company incurred $689,264 in offering related costs which are being amortized over the life of the loan. The note payable will be converted into 592,500 of merging company common shares as part of the merger agreement dated January 25, 2013.

 

Note 11 – Subsequent Events

 

On January 25, 2013, the Company signed a definitive merger agreement to merge the Company with and into Selway . Pursuant to the agreement, Selway agreed to acquire all of the issued and outstanding securities in exchange for 5,200,000 shares of stock and 1,185,000 shares in exchange for the outstanding preferred stock and note payable. On April 10, 2013, the transactions contemplated by the agreement closed.

 

The agreement also has an earn out component that requires the Company to achieve certain financial goals. The determination shall be based on the combined company’s audited financial statements.

 

1.1.4 million shares shall be issued if the combined company achieves consolidated revenue of at least $150 million for the 12 month period ending June 30, 2014.

 

2.1.4 million shares shall be issued based if the combined company achieves consolidated revenue of at least $300 million for the 12 month period ending June 30, 2015.
a.Should #1 not be achieved but #2 is achieved, the full 2.8 million shares will be issued.

 

3.Cash Flow Note: Shareholders of record of HCCA prior to the merger shall receive a $10 million note from the company with the following provision. 25% of all free cash flow after the first $2 million of free cash flow based on audited financials will be distributed to those shareholders. The note has no expiration date.

 

4.In the case of a sale of the combined company at a price per share of at least $15 per share, all shares will be issued immediately prior to the closing and the remaining balance due on the cash flow note will be paid immediately.

 

The foregoing targets are to be met on an all-or-nothing basis, and there shall be no partial awards.

 

In addition, at the time of the merger certain members of HCCA’s management received an aggregate of 1,500,000 shares of Selway common stock, which shares were fully vested but placed in escrow to be released in three equal installments of 500,000 shares on each of September 30, 2013, June 30, 2014 and June 30, 2015. HCCA expects to record a one-time expense reflecting the estimated market value of these shares at the time of the merger.

 

F-12